Launching 1st March 2023. Also check out: https://www.thailandmedical.news/
Interleukin-6 (IL-6) is an endogenous chemical which is active in inflammation, and in B cell maturation. Besides being an immune protein, it is also a pyrogen, and is responsible for fever in autoimmune, infectious or non-infectious disease. It is produced in the body, wherever there is inflammation, either acute or chronic. This includes situations such as trauma, burns, cancers and infection. It interacts with interleukin-6 receptor alpha, to induce transcription of inflammatory gene products.
Interleukin-6 is implicated in a host of chronic disease conditions associated with inflammation. Interleukin-6 is also suspected to cause increased susceptibility to diabetes mellitus, and to the systemic form of juvenile rheumatoid arthritis.
Interleukin-6 is released by monocytes and macrophages in response to other inflammatory cytokines which include interleukin-11, and tumor necrosis factor (TNF)-beta. The IL-6 receptor is present on normal T-lymphocytes in the resting phase, normal activated B-cells, and cells in the myeloid and hepatic cell lines. It is also found on B cells modified by the Epstein-Barr virus.
Interleukin-6 produces inflammatory effects by inducing the transcription of factors in multiple pathways of inflammation. These may originate with protein kinase C, cAMP/ protein kinase A, and calcium release. IL-6 is a molecule with multiple forms and functions, depending on where it is secreted. These include:
Thus IL-6 participates in the short-term defence against infection or injury, and warns the immune system against the source of inflammation. However, defective regulation of this molecule results in disease.
Interleukin-6 deficiency has profound effects on immune activation and IgA antibodies. On the other hand, interleukin-6 overexpression has equally important effects. Acting through different pathways, IL-6 creates an immunological imbalance between Th-17 cells and Treg cells, resulting in autoimmune pathology. Defective IL-6 regulation may also produce lymphoid malignancies, and may be due to a mutation in the IL-6 gene.
Tocilizumab, a drug which inhibits the interleukin-6 receptor, has been studied as a therapeutic helper in a variety of chronic inflammatory disorders, including rheumatoid arthritis, juvenile rheumatoid arthritis, and Castleman’s disease. Interleukin-6 is also used as a biological response modifier. It is used to enhance the response to chemotherapy by stimulating the immune response in cancer.